Skip to main content
eScholarship
Open Access Publications from the University of California

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

  • Author(s): Weiner, MW
  • Veitch, DP
  • Aisen, PS
  • Beckett, LA
  • Cairns, NJ
  • Green, RC
  • Harvey, D
  • Jack, CR
  • Jagust, W
  • Morris, JC
  • Petersen, RC
  • Salazar, J
  • Saykin, AJ
  • Shaw, LM
  • Toga, AW
  • Trojanowski, JQ
  • et al.

Published Web Location

http://www.sciencedirect.com/science/article/pii/S1552526016330722?via=ihub
No data is associated with this publication.
Abstract

© 2016 the Alzheimer's Association Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. Methods ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item